Abstract
Drug delivery to the eye still is a challenge due to its intricate anatomical structure. Posterior segment delivery is much more challenging due to the acellular nature of the vitreous humor and the longer diffusion distance to the retina. Iontophoresis is a noninvasive technique that facilitates the movement of charged drug molecules into tissues by an electric field. Using iontophoresis, it is possible to achieve therapeutic concentrations faster by modulating the intensity and duration of the applied current. Transscleral iontophoretic delivery is gaining pace and is considered as an alternative for a safe and more effective treatment to retinal disorders. This chapter intends to highlight various aspects of iontophoresis, with a special emphasis on transscleral delivery of drugs and drug-loaded nanocarrier systems for treating disorders in the back of the eye. Finally, a section on toxic effects of iontophoresis to various ocular tissues is included.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Pal Kaur I, Kanwar M. Ocular preparations: the formulation approach. Drug Dev Ind Pharm. 2002;28(5):473–93.
HS Boddu S. Polymeric nanoparticles for ophthalmic drug delivery: an update on research and patenting activity. Recent Pat Nanomed. 2012;2(2):96–112.
Ranta V-P, et al. Barrier analysis of periocular drug delivery to the posterior segment. J Control Release. 2010;148(1):42–8.
HS Boddu S, Gupta H, Patel S. Drug delivery to the back of the eye following topical administration: an update on research and patenting activity. Recent Pat Drug Deliv Formul. 2014;8(1):27–36.
Thompson JT. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol. 2006;141(4):629–37.
Ozkiris A, Erkilic K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol. 2005;40(1):63–8.
Rhee DJ, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol. 2006;90(8):999–1003.
Jonas JB. Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res. 2006;38(4):218–45.
Sanborn GE, et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. Arch Ophthalmol. 1992;110(2):188–95.
Janoria KG, et al. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv. 2007;4(4):371–88.
Short BG. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol Pathol. 2008;36(1):49–62.
Gaudana R, et al. Recent perspectives in ocular drug delivery. Pharm Res. 2009;26(5):1197–216.
Russell R. Bioerodable eye implant may help treat macular edema. Pharm Technol. 2004;28(3):18.
Ambati J, et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci. 2000;41(5):1186–91.
Jiang J, et al. Intrascleral drug delivery to the eye using hollow microneedles. Pharm Res. 2009;26(2):395–403.
Bourges J-L, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci. 2003;44(8):3562–9.
Patel S, et al. Development and evaluation of dexamethasone Nanomicelles with potential for treating posterior uveitis after topical application. J Ocul Pharmacol Ther. 2015;31(4):215–27.
Vadlapudi AD, Mitra AK. Nanomicelles: an emerging platform for drug delivery to the eye. Ther Deliv. 2013;4(1):1.
Olsen TW, et al. Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment. Am J Ophthalmol. 2006;142(5):777–87. e2
Normand N, et al. VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo. Mol Vis. 2005;11:184–91.
Eljarrat-Binstock E, Domb AJ. Iontophoresis: a non-invasive ocular drug delivery. J Control Release. 2006;110(3):479–89.
Thrimawithana TR, et al. Drug delivery to the posterior segment of the eye. Drug Discov Today. 2011;16(5):270–7.
Kompella UB, Kadam RS, Lee VH. Recent advances in ophthalmic drug delivery. Ther Deliv. 2010;1(3):435–56.
Molokhia SA, et al. Examination of barriers and barrier alteration in transscleral iontophoresis. J Pharm Sci. 2008;97(2):831–44.
Masada T, et al. Examination of iontophoretic transport of ionic drugs across skin: baseline studies with the four-electrode system. Int J Pharm. 1989;49(1):57–62.
Srinivasan V, et al. Transdermal iontophoretic drug delivery: mechanistic analysis and application to polypeptide delivery. J Pharm Sci. 1989;78(5):370–5.
Khan A, et al. Iontophoretic drug delivery: history and applications. J App Pharm Sci. 2011;1:11.
Alkilani AZ, McCrudden MT, Donnelly RF. Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics. 2015;7(4):438–70.
Leduc S. Introduction of medicinal substances into the depth of tissues by electric current. Ann Electrobiol. 1900;3:545–60.
Chien YW, Banga AK. Iontophoretic (transdermal) delivery of drugs: overview of historical development. J Pharm Sci. 1989;78(5):353–4.
Wirtz R. Die ionentherapie in der augenheilkunde. Klin Monatsbl Augenheilkd. 1908;46:543–79.
Karbowski M. Iontophoresis in ophthalmology (part 1 of 2). Ophthalmologica. 1939;97(3–4):166–83.
Birkhauser R. Resultats d’etudes cliniques et experimentales sur la iontophorese. Rev Gen Ophtalmol. 1921;35:312–8.
Fietta P. Quelques essais d’iontophorese a l’atropine. Rev Gen Ophtalmol. 1924;38:317–28.
Morisot L. L'ionothérapie ou ionisation appliquée au traitement des affections oculaires. Clin Ophthalmol. 1927;31:5–16.
von Sallmann L. Sulfadiazine iontophoresis in pyocyaneus infection of rabbit cornea. Am J Ophthalmol. 1942;25(11):1292–300.
Von Sallmann L. Further efforts to influence X-ray cataract by chemical agents. Trans Am Ophthalmol Soc. 1951;49:391.
Von Sallmann L. Experimental study on the vitreous: II. Experiments on disappearance of red blood cells from the vitreous. Arch Ophthalmol. 1950;43(4):638–52.
von Sallmann L, Dillon B. Studies of the eye with radioiodine autographs. Am J Ophthalmol. 1950;33(3):429–40.
von Sallmann L, et al. Study on penetration of cysteine and cystine into the aqueous humor of rabbits and its relation to early x-irradiation effects on the eye. Am J Ophthalmol. 1951;34(5):95–103.
Maurice DM. Iontophoresis of fluorescein into the posterior segment of the rabbit eye. Ophthalmology. 1986;93(1):128–32.
Barza M, Peckman C, Baum J. Transscleral iontophoresis of cefazolin, ticarcillin, and gentamicin in the rabbit. Ophthalmology. 1986;93(1):133–9.
Hughes L, Maurice DM. A fresh look at iontophoresis. Arch Ophthalmol. 1984;102(12):1825–9.
Behar-Cohen FF, et al. Ocular iontophoresis. In: Drug product development for the back of the eye: Springer, Boston, MA; 2011. p. 361–90.
Bejjani RA, et al. Electrically assisted ocular gene therapy. Surv Ophthalmol. 2007;52(2):196–208.
Li S, Hao J, Liddell M. Electrotransport across membranes in biological media: Electrokinetic theories and applications in drug delivery. In: Transport in biological media. Philadelphia: Elsevier; 2013. Ch 11.
Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems: a shift to the posterior segment. Drug Discov Today. 2008;13(3):135–43.
Gratieri T, Kalia YN. Mathematical models to describe iontophoretic transport in vitro and in vivo and the effect of current application on the skin barrier. Adv Drug Deliv Rev. 2013;65(2):315–29.
Sarraf D, LEE DA. The role of iontophoresis in ocular drug delivery. J Ocul Pharmacol Ther. 1994;10(1):69–81.
Behar-Cohen FF, et al. Iontophoresis of dexamethasone in the treatment of endotoxin-induced-uveitis in rats. Exp Eye Res. 1997;65(4):533–45.
Behar-Cohen F, et al. Transscleral coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels. Exp Eye Res. 2002;74(1):51–9.
Hayden BC, et al. Pharmacokinetics of systemic versus focal carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of retinoblastoma. Invest Ophthalmol Vis Sci. 2004;45(10):3644–9.
Voigt M, et al. Ocular aspirin distribution: a comparison of intravenous, topical, and coulomb-controlled iontophoresis administration. Invest Ophthalmol Vis Sci. 2002;43(10):3299–306.
Dehghan M, Mouzam M. Advances in iontophoresis for drug delivery. Int J Health Res. 2008;1(3):115.
Halhal M, et al. Iontophoresis: from the lab to the bed side. Exp Eye Res. 2004;78(3):751–7.
Güngör S, et al. Trans-scleral iontophoretic delivery of low molecular weight therapeutics. J Control Release. 2010;147(2):225–31.
Jones R, Maurice D. New methods of measuring the rate of aqueous flow in man with fluorescein. Exp Eye Res. 1966;5(3):208–20.
Frucht-Pery J, et al. Iontophoresis–gentamicin delivery into the rabbit cornea, using a hydrogel delivery probe. Exp Eye Res. 2004;78(3):745–9.
Eljarrat-Binstock E, et al. Delivery of gentamicin to the rabbit eye by drug-loaded hydrogel iontophoresis. Invest Ophthalmol Vis Sci. 2004;45(8):2543–8.
Eljarrat-Binstock E, et al. Transcorneal and transscleral iontophoresis of dexamethasone phosphate using drug loaded hydrogel. J Control Release. 2005;106(3):386–90.
Eljarrat-Binstock E, et al. Hydrogel probe for iontophoresis drug delivery to the eye. J Biomater Sci Polym Ed. 2004;15(4):397–413.
Vollmer DL, et al. In vivo transscleral iontophoresis of amikacin to rabbit eyes. J Ocul Pharmacol Ther. 2002;18(6):549–58.
Myles ME, Neumann DM, Hill JM. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev. 2005;57(14):2063–79.
Hastings MS, et al. Visulex: advancing iontophoresis for effective noninvasive back-of-the-eye therapeutics. Drug Delivery Tech. 2004;4:53–7.
Pescina S, et al. Effect of formulation factors on the trans-scleral iontophoretic and post-iontophoretic transports of a 40kDa dextran in vitro. Eur J Pharm Sci. 2011;42(5):503–8.
Frucht-Pery J, et al. Iontophoretic treatment of experimental pseudomonas keratitis in rabbit eyes using gentamicin-loaded hydrogels. Cornea. 2006;25(10):1182–6.
Myles ME, Loutsch JM, Higaki S, Hill JM. Ocular iontophoresis: ophthalmic drug delivery systems. New York: Marcel Dekker; 2002.
Hill JM, O'Callaghan RJ, Hobden JA. Ocular iontophoresis: ophthalmic drug delivery systems. New York: Marcel Dekker; 1993.
Miller LL, Smith GA. Iontophoretic transport of acetate and carboxylate ions through hairless mouse skin. A cation exchange membrane model. Int J Pharm. 1989;49(1):15–22.
Nicoli S, et al. Porcine sclera as a model of human sclera for in vitro transport experiments: histology, SEM, and comparative permeability. Mol Vis. 2009;15:259.
Berner B, Dinh SM. Electronically controlled drug delivery: CRC Press, Boca Raton, FL; 1998.
Green PG, et al. Lontophoretic delivery of amino acids and amino acid derivatives across the skin in vitro. Pharm Res. 1991;8(9):1113–20.
Li SK, et al. Influence of asymmetric donor–receiver ion concentration upon transscleral iontophoretic transport. J Pharm Sci. 2005;94(4):847–60.
Bockris JOM, Reddy AK. Modern electrochemistry 2B: electrodics in chemistry, engineering. In: Biology and environmental science, vol. 2: Springer Science & Business Media, Boston, MA; 2000.
Chopra P, Hao J, Li SK. Iontophoretic transport of charged macromolecules across human sclera. Int J Pharm. 2010;388(1):107–13.
Sung K, Fang J-Y, Hu OY-P. Delivery of nalbuphine and its prodrugs across skin by passive diffusion and iontophoresis. J Control Release. 2000;67(1):1–8.
Hayden B, et al. Iontophoretic delivery of carboplatin in a murine model of retinoblastoma. Invest Ophthalmol Vis Sci. 2006;47(9):3717–21.
Siddiqui O, et al. Facilitated transdermal transport of insulin. J Pharm Sci. 1987;76(4):341–5.
Phipps J, Padmanabhan R, Lattin G. Iontophoretic delivery model inorganic and drug ions. J Pharm Sci. 1989;78(5):365–9.
Rawat S, et al. Transdermal delivery by iontophoresis. Indian J Pharm Sci. 2008;70(1):5.
Molokhia S, et al. The influence of formulation factors on Transscleral Iontophoretic delivery of a macromolecule in vitro and in vivo. Invest Ophthalmol Vis Sci. 2013;54(15):3204.
Kirubakaran N, Chandrika M, Rani KRV. Iontophoresis: controlled transdermal drug delivery system. Int J Pharm Sci Res. 2015;6(8):3174.
Molokhia SA, et al. Examination of penetration routes and distribution of ionic permeants during and after transscleral iontophoresis with magnetic resonance imaging. Int J Pharm. 2007;335(1):46–53.
Banga AK, Chien YW. Iontophoretic delivery of drugs: fundamentals, developments and biomedical applications. J Control Release. 1988;7(1):1–24.
Abramowitz D, Neoussikine B. Treatment by ion transfer, vol. 87. New York: Grune and Stratton; 1946.
Lee TW-Y, Robinson JR. Drug delivery to the posterior segment of the eye II: development and validation of a simple pharmacokinetic model for subconjunctival injection. J Ocul Pharmacol Ther. 2004;20(1):43–53.
Robinson MR, et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res. 2006;82(3):479–87.
Li SK, Molokhia SA, Jeong E-K. Assessment of subconjunctival delivery with model ionic permeants and magnetic resonance imaging. Pharm Res. 2004;21(12):2175–84.
Kim H, et al. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci. 2004;45(8):2722–31.
Li SK, Jeong E-K, Hastings MS. Magnetic resonance imaging study of current and ion delivery into the eye during transscleral and transcorneal iontophoresis. Invest Ophthalmol Vis Sci. 2004;45(4):1224–31.
Molokhia SA, et al. Transscleral iontophoretic and intravitreal delivery of a macromolecule: study of ocular distribution in vivo and postmortem with MRI. Exp Eye Res. 2009;88(3):418–25.
Holash JA, Stewart PA. The relationship of astrocyte-like cells to the vessels that contribute to the blood-ocular barriers. Brain Res. 1993;629(2):218–24.
Barza M, Peckman C, Baum J. Transscleral iontophoresis as an adjunctive treatment for experimental endophthalmitis. Arch Ophthalmol. 1987;105(10):1418–20.
CHOI TB, LEE DA. Transscleral and transcorneal iontophoresis of vancomycin in rabbit eyes. J Ocul Pharmacol Ther. 1988;4(2):153–64.
YOSHIZUMI MO, et al. Experimental transscleral iontophoresis of ciprofloxacin. J Ocul Pharmacol Ther. 1991;7(2):163–7.
Raiskup-Wolf F, et al. Delivery of gentamicin to the rabbit eye using hydrogel and iontophoresis. Ceska a slovenska oftalmologie: casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti. 2006;62(3):175–82.
Edelhauser HF, et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci. 2010;51(11):5403–20.
Lam TT, et al. Transscleral iontophoresis of dexamethasone. Arch Ophthalmol. 1989;107(9):1368–71.
Higuchi W, et al. Delivery of sustained release formulation of triamcinolone acetonide to the rabbit eye using the VisulexTM ocular iontophoresis device. Invest Ophthalmol Vis Sci. 2006;47(13):5108.
Eljarrat-Binstock E, et al. Methylprednisolone delivery to the back of the eye using hydrogel iontophoresis. J Ocul Pharmacol Ther. 2008;24(3):344–50.
Kralinger MT, et al. Ocular delivery of acetylsalicylic acid by repetitive coulomb-controlled iontophoresis. Ophthalmic Res. 2003;35(2):102–10.
Patane MA, et al. Evaluation of ocular and general safety following repeated dosing of dexamethasone phosphate delivered by transscleral iontophoresis in rabbits. J Ocul Pharmacol Ther. 2013;29(8):760–9.
Chopra P, Hao J, Li SK. Sustained release micellar carrier systems for iontophoretic transport of dexamethasone across human sclera. J Control Release. 2012;160(1):96–104.
Hayden BH, et al. Subconjunctival carboplatin in retinoblastoma: impact of tumor burden and dose schedule. Arch Ophthalmol. 2000;118(11):1549–54.
Eljarrat–Binstock E, et al. Methotrexate delivery to the eye using transscleral hydrogel iontophoresis. Curr Eye Res. 2007;32(7–8):639–46.
Lam TT, et al. Intravitreal delivery of ganciclovir in rabbits by transscleral iontophoresis. J Ocul Pharmacol Ther. 1994;10(3):571–5.
Sarraf D, et al. Transscleral iontophoresis of foscarnet. Am J Ophthalmol. 1993;115(6):748–54.
Yoshizumi MO, et al. Determination of ocular toxicity in multiple applications of foscarnet iontophoresis. J Ocul Pharmacol Ther. 1997;13(6):529–36.
Asahara T, et al. Induction of gene into the rabbit eye by iontophoresis: preliminary report. Jpn J Ophthalmol. 2001;45(1):31–9.
Voigt M, et al. Down-regulation of NOSII gene expression by iontophoresis of anti-sense oligonucleotide in endotoxin-induced uveitis. Biochem Biophys Res Commun. 2002;295(2):336–41.
Pescina S, et al. In-vitro permeation of bevacizumab through human sclera: effect of iontophoresis application. J Pharm Pharmacol. 2010;62(9):1189–94.
Tratta E, et al. In vitro permeability of a model protein across ocular tissues and effect of iontophoresis on the transscleral delivery. Eur J Pharm Biopharm. 2014;88(1):116–22.
Chauvaud D, et al. Transscleral Iontophoresis of corticosteroids: phase II clinical trial. In: Investigative Ophthalmology & Visual Science. Rockville Pike: Assoc Research Vision Ophthalmology INC 9650; 2000.
Halhal M, et al. Corneal graft rejection and corticoid iontophoresis: 3 case reports. J Fr Ophtalmol. 2003;26(4):391–5.
Behar-Cohen F, et al. Reversal of corneal graft rejection by iontophoresis of methylprednisolone. Invest Ophthalmol Vis Sci. 2002;43(13):2214.
Parkinson T, et al. Tolerance of ocular iontophoresis in healthy volunteers. Invest Ophthalmol Vis Sci. 2002;43(13):1854.
Horwath-Winter J, et al. Iodide iontophoresis as a treatment for dry eye syndrome. Br J Ophthalmol. 2005;89(1):40–4.
Cohen A, et al. Clinical experience with the EyeGate® II delivery system (EGDS): safety and tolerability in healthy adult volunteers. Invest Ophthalmol Vis Sci. 2011;52(14):3224.
Domb AJ, Khan W. Focal controlled drug delivery: Springer Science & Business Media, Boston, MA; 2014.
Eljarrat-Binstock E, et al. Charged nanoparticles delivery to the eye using hydrogel iontophoresis. J Control Release. 2008;126(2):156–61.
Wu C, Huang D, Wang L, Dong Y. A novel technology using transscleral iontophoresis to deliver protein drug-loaded nanoparticles to the posterior eye segment 2013; Available from: http://abstracts.aaps.org/Verify/aaps2013/postersubmissions/M1054.pdf.
Schoellhammer CM, Blankschtein D, Langer R. Skin permeabilization for transdermal drug delivery: recent advances and future prospects. Expert Opin Drug Deliv. 2014;11(3):393–407.
Yoshizumi MO, et al. Ocular toxicity of iontophoretic foscarnet in rabbits. J Ocul Pharmacol Ther. 1995;11(2):183–9.
Burnette RR, Marrero D. Comparison between the iontophoretic and passive transport of thyrotropin releasing hormone across excised nude mouse skin. J Pharm Sci. 1986;75(8):738–43.
Barza M, Peckman C, Baum J. Transscleral iontophoresis of gentamicin in monkeys. Invest Ophthalmol Vis Sci. 1987;28(6):1033–6.
Lam TT, Fu J, Tso MO. A histopathologic study of retinal lesions inflicted by transscleral iontophoresis. Graefes Arch Clin Exp Ophthalmol. 1991;229(4):389–94.
Grossman RE, Chu DF, Lee DA. Regional ocular gentamicin levels after transcorneal and transscleral iontophoresis. Invest Ophthalmol Vis Sci. 1990;31(5):909–16.
Gratieri T, Santer V, Kalia YN. Basic principles and current status of transcorneal and transscleral iontophoresis. Expert Opin Drug Deliv. 2017 Sep;14(9):1091–1102.
Rajendra Vivek B. et al. Ocular iontophoresis: a review. Inventi impact: NDDS; 2010.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Bahl, D., Bachu, R.D., Chitti, M., Chowdhury, P., Renukuntla, J., Boddu, S.H.S. (2018). Transscleral Iontophoretic Drug Delivery for Treating Retinal Diseases. In: Patel, J., Sutariya, V., Kanwar, J., Pathak, Y. (eds) Drug Delivery for the Retina and Posterior Segment Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-95807-1_14
Download citation
DOI: https://doi.org/10.1007/978-3-319-95807-1_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95806-4
Online ISBN: 978-3-319-95807-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)